查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1836788

非何傑金氏淋巴瘤治療市場（按治療類型、細胞類型、給藥途徑、患者年齡層和最終用戶分類）—2025-2032 年全球預測

Non-Hodgkin Lymphoma Treatment Market by Treatment Type, Cell Type, Route of Administration, Patient Age Group, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年非何傑金氏淋巴瘤治療市場將成長至 188.3 億美元，複合年成長率為 8.97%。

主要市場統計數據
基準年2024年 94.6億美元
預計2025年 102.6億美元
預測年份：2032年 188.3億美元
複合年成長率（%） 8.97%

多方面的臨床、監管和商業性力量決定了非何傑金氏淋巴瘤的治療策略

非何傑金氏淋巴瘤代表一組形態各異的骨髓惡性腫瘤，持續對臨床醫師、支付者和創新者構成挑戰。免疫療法、分子標靶藥物和細胞療法的最新進展重新定義了多種亞型的臨床治療路徑，而診斷和風險分層工具的改進也使得更個人化的治療方法成為可能。本介紹提供了臨床、監管和商業性背景，以支援研發和上市團隊目前的策略決策。

不斷發展的治療模式正在推動腫瘤學家、血液學家和相關專家之間的多學科合作，為整個醫療領域帶來了機會和挑戰。醫療保健系統難以將高成本、高療效的治療方法納入現有的方案和護理路徑，而支付方也越來越重視真實世界證據和基於價值的安排。因此，相關人員必須應對不斷變化的報銷環境、傾向於加速核准的監管趨勢以及新型作用機制的競爭動態。本節重點在於臨床創新與商業性準備的交匯，為後續的詳細分析奠定基礎，這些分析將塑造近期的策略。

確定關鍵的臨床、監管和商業轉型，重新定義非何傑金氏淋巴瘤治療的開發和應用

非何傑金氏淋巴瘤的治療格局正被多種力量匯聚而成，這些力量正在改變治療方法的開發、核准和應用方式。首先，精準醫療和分子分析正從小眾領域走向主流，使得B細胞、T細胞和NK細胞淋巴瘤的分類更加精細，並為標靶標靶治療方法提供資訊。其次，細胞療法和雙特異性抗體的成熟，正在擴大治癒和持久緩解的可能性，超越傳統的化療和放射線治療，促使人們重新評估治療順序和聯合策略。

同時，法律規範也在不斷發展，以適應加速核准流程和有條件核准，這增加了核准後證據產生的重要性。健康技術評估流程正在適應新的終點和病患報告結果，重塑證據產生規劃。在商業性方面，生物技術創新者與成熟製藥公司之間的夥伴關係正在加速後期開發和全球商業化，而數位療法和遠端醫療正在加強患者監測和生存期護理。總而言之，這些轉變需要一項涵蓋臨床開發、真實世界證據、定價和相關人員參與的整合策略，以充分發揮新治療方法的潛力。

評估2025年美國關稅調整對供應鏈彈性、成本管理和商業性准入策略的多面向影響

2025年影響貿易和進口關稅的政策變化，為醫藥供應鏈、定價策略和跨境臨床試驗物流規劃帶來了新的變數。關稅調整可能會影響原料藥、生技藥品成品和醫療設備的到達成本，迫使製造商重新評估籌資策略和庫存配置。為此，企業正在加快供應鏈恢復工作，包括雙重採購、關鍵零件近岸外包以及策略性儲備，以減輕潛在的中斷和成本增加。

除了直接的成本影響外，關稅還會透過改變支付方和醫療服務提供者之間的淨定價和報銷談判，影響商業策略。製藥公司擴大參與情境規劃，以了解關稅引發的成本壓力將如何影響合約談判和競標結果。此外，為了最大限度地降低關稅波動的影響，臨床開發和生產領域的跨國合作正在重新評估。這些累積效應使得製藥公司更加重視靈活的生產方式、多元化的供應商網路以及與相關人員的主動溝通，以保障非何傑金氏淋巴瘤患者的治療可及性和持續性。

整合治療方式、細胞亞型、給藥途徑、患者人口統計和醫療保健環境的可操作細分洞察

準確了解臨床和商業細分市場對於使開發項目和商業發布計劃與未滿足的需求和治療途徑保持一致至關重要。基於治療類型的分析考慮了化療、免疫療法、放射放射線治療、幹細胞移植和標靶治療，以及每種療法如何與目前方案中的定序、聯合治療潛力和耐受性相互作用。 B 細胞淋巴瘤進一步分為套件淋巴瘤、瀰漫大 B 細胞淋巴瘤 (DLBCL) 和濾泡性淋巴瘤，而 T 細胞淋巴瘤進一步分為異生性大細胞淋巴瘤、皮膚 T 細胞淋巴瘤和周邊 T 細胞淋巴瘤，每種淋巴瘤都代表著不同的治療需求和臨床試驗考慮因素。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • CAR-T細胞療法的快速普及推動了復發和難治性非何傑金氏淋巴瘤治療模式轉移
  • 雙特異性抗體療法的出現擴大了侵襲性 B 細胞淋巴瘤的現成免疫療法選擇
  • 整合微量殘存疾病監測來指導濾泡性淋巴瘤治療的個人化維護策略
  • 小分子標靶抑制劑的擴展增強了惰性和進行性非何傑金氏淋巴瘤一線治療的聯合治療
  • 擴大抗體藥物複合體在提高復發性瀰漫大B細胞淋巴瘤的緩解率和降低毒性方面的作用
  • 開發新型表觀調變器，為難治性周邊區域淋巴瘤提供新的治療途徑
  • 數位診斷與人工智慧驅動的生物標記的增強整合將加速非何傑金氏淋巴瘤的早期發現和個人化治療
  • 支付方和報銷趨勢影響淋巴瘤治療中昂貴的免疫療法和生物相似藥的可及性
  • 雙特異性抗體的出現徹底改變了復發性非何傑金氏淋巴瘤的治療模式
  • CAR-T 細胞療法的廣泛應用顯著改善了侵襲性 NHL 亞型的治療效果

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

非何傑金氏淋巴瘤治療市場（依治療類型）

  • 化療
  • 免疫療法
  • 放射治療
  • 幹細胞移植
  • 標靶治療

非何傑金氏淋巴瘤治療市場（依細胞類型）

  • B細胞淋巴瘤
    • 套件淋巴瘤
    • 瀰漫大B細胞淋巴瘤（DLBCL）
    • 濾泡性淋巴瘤
    • 套細胞淋巴瘤
    • 周邊區域淋巴瘤
  • NK細胞淋巴瘤
  • T細胞淋巴瘤
    • 異生性大細胞淋巴瘤
    • 皮膚T細胞淋巴瘤
    • 周邊T細胞淋巴瘤

非何傑金氏淋巴瘤治療市場

  • 靜脈輸液
  • 口服
  • 皮下注射

非何傑金氏淋巴瘤治療市場（依患者年齡層）

  • 成人
  • 老年人
  • 孩子們

非何傑金氏淋巴瘤治療市場（依最終用戶）

  • 門診手術中心
  • 癌症治療中心
  • 醫院

非何傑金氏淋巴瘤治療市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

非何傑金氏淋巴瘤治療市場：按組

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

非何傑金氏淋巴瘤治療市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • AbbVie Inc.
    • AstraZeneca PLC
    • Bayer AG
    • BeiGene, Ltd.
    • Bristol-Myers Squibb Company
    • Cipla Inc.
    • Dr. Reddy's Laboratories Ltd.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd
    • Gilead Sciences, Inc.
    • GlaxoSmithKline PLC
    • Hikma Pharmaceuticals PLC
    • Intas Pharmaceuticals Ltd.
    • Kyowa Kirin Co., Ltd.
    • Lupin Ltd.
    • Merck & Co., Inc.
    • Novartis AG
    • Salvavidas Pharmaceutical Pvt. Ltd.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
    • Zydus Pharmaceuticals
Product Code: MRR-036C5CF3B518

The Non-Hodgkin Lymphoma Treatment Market is projected to grow by USD 18.83 billion at a CAGR of 8.97% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 9.46 billion
Estimated Year [2025] USD 10.26 billion
Forecast Year [2032] USD 18.83 billion
CAGR (%) 8.97%

A comprehensive orientation to the multifaceted clinical, regulatory, and commercial forces shaping Non-Hodgkin Lymphoma treatment strategies across care settings

Non-Hodgkin Lymphoma represents a diverse group of hematologic malignancies that continues to challenge clinicians, payers, and innovators in equal measure. Recent advances in immunotherapies, targeted agents, and refinements in cellular therapies have rewritten clinical pathways for many subtypes, while diagnostic improvements and risk stratification tools are enabling more personalized approaches to care. This introduction establishes the clinical, regulatory, and commercial context that underpins current strategic decision-making across research, development, and market access teams.

The evolving treatment paradigm has created opportunities and complexities across care settings, prompting multidisciplinary collaboration among oncologists, hematologists, and allied specialists. Health systems are grappling with integrating high-cost, high-impact therapies into existing formularies and care pathways, and payers are increasingly focused on real-world evidence and value-based arrangements. Consequently, stakeholders must navigate shifting reimbursement environments, regulatory pathways that prioritize accelerated approvals, and competitive dynamics driven by novel mechanisms of action. This section sets the stage for the deeper analysis that follows, highlighting the intersections of clinical innovation and commercial readiness that will shape near-term strategy.

Identifying the pivotal clinical, regulatory, and commercial transformations that are redefining therapeutic development and adoption in Non-Hodgkin Lymphoma care

The landscape for Non-Hodgkin Lymphoma treatment is being transformed by several convergent forces that are altering how therapies are developed, approved, and adopted. First, precision medicine and molecular profiling have moved from niche to mainstream, enabling more granular classification of B-cell, T-cell, and NK-cell lymphomas and informing targeted therapeutic approaches. Second, the maturation of cellular therapies and bispecific antibodies is expanding curative and durable response possibilities beyond traditional chemotherapy and radiation, prompting a re-evaluation of sequencing and combination strategies.

Simultaneously, regulatory frameworks are evolving to accommodate accelerated pathways and conditional approvals, increasing the importance of post-approval evidence generation. Health technology assessment processes are adapting to novel endpoints and patient-reported outcomes, which is reshaping evidence generation plans. On the commercial front, partnerships between biotech innovators and established pharmaceutical companies are accelerating late-stage development and global commercialization, while digital therapeutics and telehealth are enhancing patient monitoring and survivorship care. Taken together, these shifts demand integrated strategies that span clinical development, real-world evidence, pricing, and stakeholder engagement to realize the full potential of new therapies.

Evaluating the multifaceted repercussions of United States tariff adjustments in 2025 on supply chain resilience, cost management, and commercial access strategies

Policy changes affecting trade and import tariffs in 2025 have introduced new variables into planning for drug supply chains, pricing strategies, and cross-border clinical trial logistics. Tariff adjustments can influence the landed cost of active pharmaceutical ingredients, finished biologics, and medical devices, leading manufacturers to reassess sourcing strategies and inventory positioning. In response, organizations are accelerating supply-chain resilience efforts, including dual-sourcing, nearshoring of critical components, and strategic stockpiling to mitigate the potential for disruption and cost escalation.

Beyond direct cost impacts, tariffs influence commercial strategies by altering net pricing calculations and reimbursement negotiations across payers and providers. Pharmaceutical companies are increasingly engaging in scenario planning to understand how incremental tariff-driven cost pressures could affect contract negotiations and tender outcomes. Additionally, cross-border collaborations in clinical development and manufacturing are being reevaluated to minimize exposure to tariff volatility. The cumulative effect is a heightened emphasis on flexible manufacturing, diversified supplier networks, and proactive stakeholder communication to preserve access and maintain the continuity of care for patients with Non-Hodgkin Lymphoma.

Actionable segmentation insights that integrate treatment modalities, cellular subtypes, administration routes, patient age demographics, and healthcare delivery settings

A precise understanding of clinical and commercial segments is essential to align development programs and commercial launch plans with unmet need and care pathways. Based on Treatment Type, analysis considers Chemotherapy, Immunotherapy, Radiation Therapy, Stem Cell Transplant, and Targeted Therapy and how each modality interacts with sequencing, combinability, and tolerability in contemporary regimens. Based on Cell Type, differentiation among B-cell Lymphomas, NK-cell Lymphomas, and T-cell Lymphomas is central to strategy, with B-cell Lymphomas further broken down into Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Mantle Cell Lymphoma, and Marginal Zone Lymphoma, and T-cell Lymphomas further categorized into Anaplastic Large Cell Lymphoma, Cutaneous T-Cell Lymphoma, and Peripheral T-Cell Lymphoma, each presenting distinct therapeutic needs and clinical trial considerations.

Based on Route of Administration, distinctions between Intravenous Infusion, Oral, and Subcutaneous Injection influence patient preference, adherence, and site-of-care economics. Based on Patient Age Group, the adult, geriatric, and pediatric populations exhibit varying comorbidity profiles, tolerability constraints, and long-term survivorship considerations that should inform dosing strategies and safety monitoring plans. Based on End User, differences in care delivery across Ambulatory Surgical Centers, Cancer Treatment Centers, and Hospitals affect reimbursement pathways, capacity planning, and clinician adoption patterns. Integrating these segmentation layers enables targeted clinical development, differentiated value propositions, and nuanced go-to-market planning.

Deep regional intelligence highlighting regulatory nuance, evidence priorities, and access pathways across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics play a critical role in shaping regulatory strategies, clinical development priorities, and commercialization pathways for Non-Hodgkin Lymphoma therapies. In the Americas, regulatory authorities and payer systems present a mix of accelerated approval mechanisms and rigorous health technology assessment processes, driving a dual focus on breakthrough designation strategies and robust real-world evidence generation. In Europe, Middle East & Africa, heterogeneous regulatory environments and disparities in access necessitate tailored market entry plans, adaptive pricing strategies, and regional partnerships to optimize uptake and patient access.

In the Asia-Pacific region, rapid expansion of clinical research capacity, growing domestic biopharma innovation, and evolving reimbursement frameworks are creating both opportunity and complexity. Local manufacturing, regional clinical trial networks, and government-led initiatives to improve cancer outcomes are shaping pathways to adoption. Across all regions, cross-border collaboration, regulatory harmonization efforts, and the localization of evidence packages are increasingly important to ensure timely approval and sustainable access. Understanding these regional nuances is essential for designing regulatory submission strategies, evidence generation plans, and commercial approaches that are responsive to local healthcare infrastructures and payer expectations.

Strategic competitive intelligence outlining how incumbent pharmaceutical groups and nimble innovators are shaping differentiation through evidence, partnerships, and delivery models

Competitive dynamics in Non-Hodgkin Lymphoma treatment are characterized by a blend of legacy oncology players and agile innovators advancing novel modalities. Established pharmaceutical companies remain critical in late-stage development, global commercialization, and manufacturing scale-up, while smaller biotechs often drive early innovation in bispecifics, ADCs, and cellular platforms. Collaborations, licensing deals, and strategic alliances are common, enabling nimble companies to leverage larger partners' regulatory and commercial expertise and enabling incumbents to refresh pipelines with innovative mechanisms of action.

The competitive landscape also reflects differentiation through evidence generation strategies, including pivotal trials focused on durable endpoints, real-world evidence programs to demonstrate effectiveness in broader populations, and biomarker-driven development to improve patient selection. Manufacturers are investing in patient support programs, hub services, and digital health tools to optimize adherence and streamline administration. As competition intensifies, companies that can demonstrate clear clinical differentiation, robust safety profiles, and pragmatic implementation models across diverse care settings will be positioned to capture clinician preference and payer support.

Practical and prioritized recommendations for industry leaders to synchronize clinical development, evidence generation, and market access strategies for durable impact

Industry leaders should prioritize an integrated strategy that aligns scientific development with commercial and access readiness. First, invest in robust biomarker and diagnostics strategies early to ensure precise patient selection and to improve the probability of regulatory success and payer acceptance. Second, design evidence-generation plans that combine randomized trials with prospective real-world studies and health economics analyses to support both regulatory approval and favorable reimbursement decisions. Third, strengthen supply chain resilience through diversified sourcing, flexible manufacturing, and contingency planning to mitigate policy-driven cost pressures and logistical disruptions.

In parallel, develop differentiated value propositions that articulate not only clinical benefits but also system-level value such as reduced hospitalizations and improved quality of life. Engage early with payers, HTA bodies, and provider networks to co-create reimbursement pathways, including outcomes-based arrangements where appropriate. Finally, foster partnerships across the ecosystem-academic centers, contract manufacturers, diagnostics providers, and patient advocacy organizations-to accelerate evidence generation and streamline adoption. These combined actions will help organizations translate therapeutic innovation into durable clinical and commercial impact.

Transparent multi-method research approach combining secondary synthesis and primary stakeholder engagement to validate clinical and commercial insights

The research underpinning this report combines comprehensive secondary analysis with targeted primary engagements to ensure rigor and relevance. Secondary inputs include peer-reviewed clinical literature, regulatory guidance documents, clinical trial registries, and payer policy publications, all synthesized to map clinical pathways, approval landscapes, and evidence gaps. Primary research incorporates structured interviews with key opinion leaders, treating physicians, payers, and patient advocacy representatives to capture nuanced perspectives on treatment preferences, barriers to adoption, and unmet needs.

Data triangulation methods were applied to reconcile divergent inputs and validate thematic conclusions. Analytical techniques included cross-validation of clinical outcomes with real-world treatment patterns, assessment of regulatory precedents against current development programs, and synthesis of commercial strategies through case-based benchmarking. Quality controls included independent expert review and an internal verification process to ensure consistency and transparency. This mixed-method approach ensures that the insights presented are grounded in clinical reality, reflective of stakeholder priorities, and actionable for strategic decision-making.

Concluding synthesis highlighting how integrated evidence, operational agility, and stakeholder engagement will determine the pace of therapeutic impact in Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma treatment is at a transformative juncture driven by targeted therapies, immunologic approaches, and more precise diagnostic frameworks. These advances offer the potential to improve patient outcomes and redefine standard-of-care sequences, yet they also introduce complexities in evidence requirements, pricing discussions, and operational readiness. Successful navigation will require coordinated strategies across development, regulatory engagement, payer interactions, and provider adoption efforts.

Looking ahead, organizations that embrace integrated evidence generation, invest in supply chain agility, and actively engage stakeholders across regions will be better positioned to translate innovation into sustainable clinical impact. The convergence of scientific progress and changing commercial dynamics presents both opportunities and responsibilities: to design therapies that meet unmet needs, to generate the evidence required for broad access, and to implement delivery models that ensure equitable patient benefit. This conclusion underscores the imperative for strategic alignment and timely action to realize the promise of new treatments for patients living with Non-Hodgkin Lymphoma.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of CAR T-cell therapies driving treatment paradigm shifts in relapsed and refractory non-Hodgkin lymphoma
  • 5.2. Emergence of bispecific antibody therapies expanding off-the-shelf immunotherapy options for aggressive B-cell lymphomas
  • 5.3. Integration of minimal residual disease monitoring guiding personalized maintenance strategies in follicular lymphoma management
  • 5.4. Expansion of targeted small molecule inhibitors enhancing frontline combination regimens in indolent and aggressive non-Hodgkin lymphoma subtypes
  • 5.5. Growing role of antibody-drug conjugates improving response rates and reducing toxicity in relapsed diffuse large B-cell lymphoma
  • 5.6. Development of novel epigenetic modulators offering new therapeutic pathways for treatment-resistant marginal zone lymphoma cases
  • 5.7. Increased integration of digital diagnostics and AI-driven biomarkers accelerating early detection and therapy customization in non-Hodgkin lymphoma
  • 5.8. Payer and reimbursement dynamics shaping access to high-cost immunotherapies and biosimilars in lymphoma care across global markets
  • 5.9. Emergence of bispecific antibodies revolutionizing treatment paradigms for relapsed non-Hodgkin lymphoma
  • 5.10. Rising adoption of CAR T-cell therapies significantly improving outcomes in aggressive NHL subtypes

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Non-Hodgkin Lymphoma Treatment Market, by Treatment Type

  • 8.1. Chemotherapy
  • 8.2. Immunotherapy
  • 8.3. Radiation Therapy
  • 8.4. Stem Cell Transplant
  • 8.5. Targeted Therapy

9. Non-Hodgkin Lymphoma Treatment Market, by Cell Type

  • 9.1. B-cell Lymphomas
    • 9.1.1. Burkitt Lymphoma
    • 9.1.2. Diffuse Large B-Cell Lymphoma (DLBCL)
    • 9.1.3. Follicular Lymphoma
    • 9.1.4. Mantle Cell Lymphoma
    • 9.1.5. Marginal Zone Lymphoma
  • 9.2. NK-cell Lymphomas
  • 9.3. T-cell Lymphomas
    • 9.3.1. Anaplastic Large Cell Lymphoma
    • 9.3.2. Cutaneous T-Cell Lymphoma
    • 9.3.3. Peripheral T-Cell Lymphoma

10. Non-Hodgkin Lymphoma Treatment Market, by Route of Administration

  • 10.1. Intravenous Infusion
  • 10.2. Oral
  • 10.3. Subcutaneous Injection

11. Non-Hodgkin Lymphoma Treatment Market, by Patient Age Group

  • 11.1. Adult
  • 11.2. Geriatric
  • 11.3. Pediatric

12. Non-Hodgkin Lymphoma Treatment Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Cancer Treatment Centers
  • 12.3. Hospitals

13. Non-Hodgkin Lymphoma Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Non-Hodgkin Lymphoma Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Non-Hodgkin Lymphoma Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. AbbVie Inc.
    • 16.3.2. AstraZeneca PLC
    • 16.3.3. Bayer AG
    • 16.3.4. BeiGene, Ltd.
    • 16.3.5. Bristol-Myers Squibb Company
    • 16.3.6. Cipla Inc.
    • 16.3.7. Dr. Reddy's Laboratories Ltd.
    • 16.3.8. Eli Lilly and Company
    • 16.3.9. F. Hoffmann-La Roche Ltd
    • 16.3.10. Gilead Sciences, Inc.
    • 16.3.11. GlaxoSmithKline PLC
    • 16.3.12. Hikma Pharmaceuticals PLC
    • 16.3.13. Intas Pharmaceuticals Ltd.
    • 16.3.14. Kyowa Kirin Co., Ltd.
    • 16.3.15. Lupin Ltd.
    • 16.3.16. Merck & Co., Inc.
    • 16.3.17. Novartis AG
    • 16.3.18. Salvavidas Pharmaceutical Pvt. Ltd.
    • 16.3.19. Sanofi S.A.
    • 16.3.20. Takeda Pharmaceutical Company Limited
    • 16.3.21. Teva Pharmaceutical Industries Ltd.
    • 16.3.22. Zydus Pharmaceuticals

LIST OF FIGURES

  • FIGURE 1. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NON-HODGKIN LYMPHOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. NON-HODGKIN LYMPHOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NON-HODGKIN LYMPHOMA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BURKITT LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BURKITT LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BURKITT LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BURKITT LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BURKITT LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BURKITT LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MARGINAL ZONE LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MARGINAL ZONE LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MARGINAL ZONE LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MARGINAL ZONE LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MARGINAL ZONE LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MARGINAL ZONE LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NK-CELL LYMPHOMAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NK-CELL LYMPHOMAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NK-CELL LYMPHOMAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NK-CELL LYMPHOMAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NK-CELL LYMPHOMAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NK-CELL LYMPHOMAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ANAPLASTIC LARGE CELL LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ANAPLASTIC LARGE CELL LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ANAPLASTIC LARGE CELL LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ANAPLASTIC LARGE CELL LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ANAPLASTIC LARGE CELL LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ANAPLASTIC LARGE CELL LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY INTRAVENOUS INFUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY INTRAVENOUS INFUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY INTRAVENOUS INFUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY INTRAVENOUS INFUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CANCER TREATMENT CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CANCER TREATMENT CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CANCER TREATMENT CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CANCER TREATMENT CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2025-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
  • TABLE 260. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2025-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 262. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
  • TABLE 274. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2025-2032 (USD MILLION)
  • TABLE 275. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
  • TABLE 276. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2025-2032 (USD MILLION)
  • TABLE 277. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 278. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 279. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC NON-HODGK